BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.0% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,134,813 shares of the biotechnology company’s stock after selling 85,264 shares during the period. Segall Bryant & Hamill LLC’s holdings in BioCryst Pharmaceuticals were worth $8,613,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Royal Bank of Canada raised its position in shares of BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 1,458 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in BioCryst Pharmaceuticals by 6.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 135,314 shares of the biotechnology company’s stock valued at $1,019,000 after acquiring an additional 8,517 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in BioCryst Pharmaceuticals by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,931,934 shares of the biotechnology company’s stock valued at $14,490,000 after acquiring an additional 640,704 shares during the last quarter. Caxton Associates LLP purchased a new position in BioCryst Pharmaceuticals in the 1st quarter worth approximately $314,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 11.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,466 shares of the biotechnology company’s stock worth $3,363,000 after purchasing an additional 47,355 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 21,773 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.65, for a total transaction of $166,563.45. Following the completion of the transaction, the insider owned 398,751 shares of the company’s stock, valued at approximately $3,050,445.15. This trade represents a 5.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

BCRX has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, December 29th. Royal Bank Of Canada cut their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Citizens Jmp lowered their price target on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, November 5th. HC Wainwright upped their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 15th. Finally, Evercore started coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $19.64.

BioCryst Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ:BCRX opened at $8.57 on Thursday. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of 7.14 and a beta of 0.74. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.31. The business has a 50-day moving average price of $7.20 and a 200 day moving average price of $7.40.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. During the same quarter last year, the firm posted ($0.13) earnings per share. BioCryst Pharmaceuticals’s revenue was up 209.1% compared to the same quarter last year. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.